

MycoBiotix

MycoBiotix is a startup company founded to develop and commercialize technologies for treatment of neuropsychiatric and autoimmune disorders. The company is particularly interested in targeting the gut microbiome using “functional foods” and natural compounds from plants, bacteria and fungi, and is currently evaluating a handful of technologies from research universities in North America and Europe.

The global mental disorder treatment market was estimated to \$48B in 2020 and with up to 71% of patients not responding to current therapies, the company aims to address significant unmet medical needs. The MycoBiotix founders are experienced pharma executives and entrepreneurs, and bring past experience in bridging the pharmaceutical and natural product industries. With a strong network and track record of pharmaceutical development and capital formation, the founders started MycoBiotix to advance and bring to market novel products for mental and autoimmune disorders that work by modulating the gut microbiome.

MycoBiotix is incorporated in Colorado with seed funding from its founders. The company has aligned with committed investors for a Series A investment to be completed later in 2021. The company has access to office space, lab space and a vivarium and utilize the founders’ extensive global network of CROs, CMOs and key opinion leaders in drug development and the medical field.

Founders

Guy Yachin, MBA

Guy Yachin is the CEO and Executive Chairman of Xerient, a drug development company focused on enhancing radiation therapy. He has served as CEO of Serpin Pharma, a Virginia based immunotherapy company, and prior of Nasvax, a company focused on the development of improved immunotherapeutics and vaccines. As the CEO he has led Vessl Ltd., a cell therapy company focused on blood vessels disorders, through clinical studies in the U.S. and Israel, financial rounds, and a keystone strategic agreement with Teva Pharmaceuticals Industries Ltd. Prior to that he was CEO and founder of Chiasma Inc. (Nasdaq:CHMA), a biotechnology company focused on the oral delivery of macromolecule drugs, where he built the company’s presence in Israel and the U.S., concluded numerous financial rounds, and guided the company’s strategy and operation for over six years. Earlier he was CEO of Naiot Technological Center Ltd., and provided seed funding and guidance to more than a dozen biomedical startups such as Remon Medical (acquired by Boston Scientific), Enzymotec (Nasdaq:ENZY). He holds a BSc. in Industrial Engineering and Management and an MBA from the Technion – Israel Institute of Technology.

Linked 

Soren Mogelsvang, PhD

Soren is the President and CEO of Exxel Pharma, a development stage therapeutics company focused on developing small molecule therapeutics for treatment of diseases with high unmet medical needs, including chronic pain, cough and PTSD. He is the co-founder of several biotech companies and brings a track record in building and leading privately funded and publicly traded companies. Recent positions he has held include President and CEO of Peak Pharmaceuticals, which he built from concept to a profitable veterinary health company; Co-founder and VP of R&D at Serpin Pharma, a clinical stage biotech company; Co-founder and Head of R&D at Caerus Discovery, an immunology company launched with support from BioWa/Kyowa Hakko Kirin and ImmunoCellular Therapeutics; and Head of Cell Biology at ATCC. Soren has PhD in Biochemistry from the University of Cambridge (UK), an MSc in Plant Molecular Biology from the University of Copenhagen (Denmark), and did postdoctoral research at the University of Colorado School of Medicine.

Linked 